coronavirus patients. "These therapies - artesunate, imatinib and infliximab – were selected by an independent expert panel for their potential in reducing the risk of death in hospitalised Covid-19 patients," the WHO said in a statement.
Artesunate is already used for severe malaria, imatinib for certain cancers, and infliximab for diseases of the immune system such as Crohn's Disease and rheumatoid arthritis.
Meanwhile, the highly-transmissible Delta variant of Covid-19 has now been reported in 135 countries, as per the WHO, which said the cumulative number of coronavirus cases reported globally could exceed 200 million by next week.
Read more on livemint.com